PMID- 24450831
OWN - NLM
STAT- MEDLINE
DCOM- 20150114
LR  - 20181202
IS  - 1937-3376 (Electronic)
IS  - 1937-3368 (Linking)
VI  - 20
IP  - 3
DP  - 2014 Jun
TI  - Status and prospects of liver cirrhosis treatment by using bone marrow-derived 
      cells and mesenchymal cells.
PG  - 206-10
LID - 10.1089/ten.TEB.2013.0527 [doi]
AB  - In 2003, we started autologous bone marrow cell infusion (ABMi) therapy for 
      treating liver cirrhosis. ABMi therapy uses 400 mL of autologous bone marrow 
      obtained under general anesthesia and infused mononuclear cells from the 
      peripheral vein. The clinical study expanded and we treated liver cirrhosis 
      induced by HCV and HBV infection and alcohol consumption. We found that the ABMi 
      therapy was effective for cirrhosis patients and now we are treating patients 
      with combined HIV and HCV infection and with metabolic syndrome-induced liver 
      cirrhosis. Currently, to substantiate our findings that liver cirrhosis can be 
      successfully treated by the ABMi therapy, we are conducting randomized 
      multicenter clinical studies designated "Advanced medical technology B" for 
      HCV-related liver cirrhosis in Japan. On the basis of our clinical study, we 
      developed a proof-of-concept showing that infusion of bone marrow cells (BMCs) 
      improved liver fibrosis and sequentially activated proliferation of hepatic 
      progenitor cells and hepatocytes, further promoting restoration of liver 
      functions. To treat patients with severe forms of liver cirrhosis, we continued 
      translational research to develop less invasive therapies by using mesenchymal 
      stem cells derived from bone marrow. We obtained a small quantity of BMCs under 
      local anesthesia and expanded them into mesenchymal stem cells that will then be 
      used for treating cirrhosis. In this review, we present our strategy to apply the 
      results of our laboratory research to clinical studies.
FAU - Terai, Shuji
AU  - Terai S
AD  - 1 Department of Gastroenterology and Hepatology, Yamaguchi University Graduate 
      School of Medicine , Yamaguchi, Japan .
FAU - Takami, Taro
AU  - Takami T
FAU - Yamamoto, Naoki
AU  - Yamamoto N
FAU - Fujisawa, Koichi
AU  - Fujisawa K
FAU - Ishikawa, Tsuyoshi
AU  - Ishikawa T
FAU - Urata, Yohei
AU  - Urata Y
FAU - Tanimoto, Haruko
AU  - Tanimoto H
FAU - Iwamoto, Takuya
AU  - Iwamoto T
FAU - Mizunaga, Yuko
AU  - Mizunaga Y
FAU - Matsuda, Takashi
AU  - Matsuda T
FAU - Oono, Takashi
AU  - Oono T
FAU - Marumoto, Miho
AU  - Marumoto M
FAU - Burganova, Guzel
AU  - Burganova G
FAU - Fernando Quintanilha, Luiz
AU  - Fernando Quintanilha L
FAU - Hidaka, Isao
AU  - Hidaka I
FAU - Marumoto, Yoshio
AU  - Marumoto Y
FAU - Saeki, Issei
AU  - Saeki I
FAU - Uchida, Koichi
AU  - Uchida K
FAU - Yamasaki, Takahiro
AU  - Yamasaki T
FAU - Tani, Kenji
AU  - Tani K
FAU - Taura, Yasuho
AU  - Taura Y
FAU - Fujii, Yasuhiko
AU  - Fujii Y
FAU - Nishina, Hiroshi
AU  - Nishina H
FAU - Okita, Kiwamu
AU  - Okita K
FAU - Sakaida, Isao
AU  - Sakaida I
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20140307
PL  - United States
TA  - Tissue Eng Part B Rev
JT  - Tissue engineering. Part B, Reviews
JID - 101466660
SB  - IM
MH  - Animals
MH  - Bone Marrow Cells/*pathology
MH  - Bone Marrow Transplantation/*trends
MH  - Cell Differentiation
MH  - Forecasting
MH  - Humans
MH  - Liver Cirrhosis/*pathology/*therapy
MH  - Liver Regeneration/*physiology
MH  - Mesenchymal Stem Cell Transplantation/*trends
MH  - Mesenchymal Stem Cells/*pathology
MH  - Tissue Engineering/trends
EDAT- 2014/01/24 06:00
MHDA- 2015/01/15 06:00
CRDT- 2014/01/24 06:00
PHST- 2014/01/24 06:00 [entrez]
PHST- 2014/01/24 06:00 [pubmed]
PHST- 2015/01/15 06:00 [medline]
AID - 10.1089/ten.TEB.2013.0527 [doi]
PST - ppublish
SO  - Tissue Eng Part B Rev. 2014 Jun;20(3):206-10. doi: 10.1089/ten.TEB.2013.0527. 
      Epub 2014 Mar 7.